Maintenance therapy for metastatic colorectal cancer
Mené en Allemagne sur 472 patients atteints d'un cancer colorectal métastatique (durée médiane de suivi : 17 mois), cet essai de phase III évalue l'efficacité, du point de vue de la durée avant progression, et la toxicité d'un traitement d'entretien à base de bévacizumab, avec ou sans fluoropyrimidine, après un traitement d'induction combinant fluoropyrimidine, oxaliplatine et bévacizumab
Although effective palliative chemotherapy has improved the outcome for most patients with advanced colorectal cancer, toxicity is a potential drawback of lengthy treatment. Therefore, to know whether a so-called drug holiday from treatment or a pause during the course of treatment can be useful or harmful to patients is a crucial point in optimising their clinical management. The AIO 0207 trial explored this issue and represents one of the major academic research efforts to improve decisions regarding the continuum of care for advanced colorectal cancer.
The Lancet Oncology , commentaire, 2014